Opus Genetics, Inc. — fact timeline

Opus Genetics, Inc. reported financial results for the first quarter ended March 31, 2026.

“On May 12, 2026 , Opus Genetics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the first quarter ended March 31, 2026 .”

Opus Genetics, Inc. incurred senior notes of $35 million with OPCM SA LLC at floating rate based on Term SOFR, subject to a floor maturing April 21, 2033.

“The initial tranche of $35 million was funded, and Notes in the aggregate amount of $35 million (the “Initial Tranche Notes”) were issued, on April 21, 2026.”

Opus Genetics, Inc. entered into Note Purchase Agreement with OPCM SA LLC valued at up to $155 million (effective 2026-04-02).

“On April 2, 2026, Opus Genetics, Inc., a Delaware corporation (the “Company”), and certain of its subsidiaries as guarantors, entered into a senior secured note purchase agreement (the “Note Purchase Agreement”) with OPCM SA LLC, as purchaser agent (“Purchaser Agent”), and certain purchasers party thereto (the “Purchasers”).”

Opus Genetics, Inc. reported the year ended December 31, 2025 results: revenue $14.2 million.

“Revenue : License and collaborations revenue totaled $14.2 million for the year ended December 31, 2025, compared to $11.0 million for the same period in 2024.”

Opus Genetics, Inc. issued 7,374,632 shares of its Series B Non-Voting Convertible Preferred Stock of preferred stock to certain purchasers for $3.39 per share for an aggregate purchase price of approximately $25.0 million.

“The Private Placement closed on February 18, 2026. Pursuant to the Securities Purchase Agreement, the Purchasers purchased the Series B Preferred Stock at a purchase price of $3.39 per share for an aggregate purchase price of approximately $25.0 million. The Company expects to use the net proceeds from the Private Placement to advance its gene therapy”

Opus Genetics, Inc. entered into Registration Rights Agreement with the Purchasers valued at Company will register the resale of shares of Common Stock issuable upon conversion of Series B Pref (effective 2026-02-18).

“In connection with the Private Placement, the Company also entered into a Registration Rights Agreement, dated February 18, 2026 (the “Registration Rights Agreement”), with the Purchasers, which provides that the Company will register the resale of the shares of Common Stock issuable upon conversion of the Series B Preferred Stock.”

Opus Genetics, Inc. entered into Securities Purchase Agreement with certain purchasers valued at Aggregate purchase price of approximately $25.0 million for 7,374,632 shares of Series B Non-Voting (effective 2026-02-13).

“On February 13, 2026, Opus Genetics, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain purchasers (the “Purchasers”) for a private placement (the “Private Placement”) of an aggregate of 7,374,632 shares of its Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”).”

Opus Genetics, Inc.: Amended and restated bylaws to enhance stockholder rights, including reducing thresholds for actions by written consent, calling special meetings, removing directors, and amending bylaws (effective 2025-03-19).

“On March 19, 2025, in connection with a periodic review of the bylaws of Opus Genetics, Inc. (the “ Company ”), the Company’s board of directors adopted amended and restated bylaws of the Company (the bylaws, as so amended and restated, the “ Amended and Restated Bylaws ”), effective immediately.”

Opus Genetics, Inc.: Amended the Restated Certificate of Incorporation to change the corporate name to Opus Genetics, Inc., effective October 23, 2024, and updated the Bylaws accordingly (effective 2024-10-23).

“Corporate Name Change to Opus Genetics, Inc. On October 22, 2024, following the Merger, Ocuphire filed an amendment to its Restated Certificate of Incorporation to change its name to “Opus Genetics, Inc.”, effective October 23, 2024.”

Opus Genetics, Inc.: Filed a Certificate of Designation for Series A Non-Voting Convertible Preferred Stock, establishing the preferences, rights, and limitations of the new series (effective 2024-10-22).

“Series A Preferred Stock On October 22, 2024, Ocuphire filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock with the Secretary of State of the State of Delaware (the “ Certificate of Designation ”) in connection with the Merger referenced in Item 1.01 above.”

Opus Genetics, Inc. completed an acquisition involving Opus Genetics Inc. (closed 2024-10-22).

“On October 22, 2024, Ocuphire completed its business combination with Opus.”

Benjamin R. Yerxa was appointed as President at Opus Genetics, Inc..

“Dr. Yerxa, age 58, has also been appointed to serve as Ocuphire’s President, effective October 22, 2024.”

Adrienne Graves was appointed as Director at Opus Genetics, Inc..

“Dr. Benjamin R. Yerxa, Ph.D., Dr. Jean Bennett, Ph.D., M.D., and Dr. Adrienne Graves, Ph.D., were appointed as members of the Board”

Jean Bennett was appointed as Director at Opus Genetics, Inc..

“Dr. Benjamin R. Yerxa, Ph.D., Dr. Jean Bennett, Ph.D., M.D., and Dr. Adrienne Graves, Ph.D., were appointed as members of the Board”

Benjamin R. Yerxa was appointed as Director at Opus Genetics, Inc..

“Dr. Benjamin R. Yerxa, Ph.D., Dr. Jean Bennett, Ph.D., M.D., and Dr. Adrienne Graves, Ph.D., were appointed as members of the Board”

Jay Pepose resigned as Director at Opus Genetics, Inc..

“Dr. Jay Pepose resigned from the Board, effective immediately after the time of the filing of the First Merger Certificate of Merger”

Opus Genetics, Inc. reported first quarter ended March 31, 2024 results: revenue $1.7 million, net income $7.1 million, EPS ($0.29).

“Financial Highlights for the First Quarter Ended March 31, 2024 As of March 31, 2024, Ocuphire had cash and cash equivalents of $47.2 million. Based on current projections, management believes that the cash on hand will be sufficient to fund operations into mid-2025. License and collaborations revenue was $1.7 million for first quarter ending March 31, 2024 compared with $1.7 million in the first quarter of 2023. Revenue during both quarterly periods was derived from the Viatris license agreement largely for the reimbursement of research and development services. During the first quarter of 2024 Ocuphire earned its first royalty payment in the amount of $3,000 stemming from the sale of RYZUMVI by Viatris in late March 2024. General and administrative expenses for the first quarter ended March 31, 2024 were $4.7 million , compared to $2.3 million for first quarter of 2023. The increase period over period was primarily attributable to increases in payroll related costs, stock-based compe”

Opus Genetics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $1.7 million and $19.0 million for the fourth quarter and year ended December 31, 2023, respectively.

“On March 8, 2024, Ocuphire Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.”

Nirav Jhaveri was appointed as Chief Financial Officer at Opus Genetics, Inc..

“On February 14, 2024, Ocuphire Pharma, Inc., (the “Company”) announced the appointment of Nirav Jhaveri as the Company’s Chief Financial Officer (“CFO”), effective February 12, 2024”

Ronil Patel changed role as Chief Business Officer at Opus Genetics, Inc..

“On December 1, 2023, the Board of Directors (the "Board" ) of Ocuphire Pharma, Inc. (the "Company" ) promoted Ronil Patel , age 40, as the Company’s Chief Business Officer, effective as of December 1, 2023.”

Joseph Schachle was appointed as Chief Operating Officer at Opus Genetics, Inc..

“On November 22, 2023, the Board of Directors (the “Board”) of Ocuphire Pharma, Inc. (the “Company”) appointed Joseph Schachle, age 58, as the Company’s Chief Operating Officer, effective as of November 27, 2023.”

Opus Genetics, Inc. reported third quarter ended September 30, 2023 results: revenue $11.9 million.

“License and collaborations revenue was $11.9 million and $17.4 million for the three and nine months ended September 30, 2023, respectively.”

Dr. George Magrath was appointed as Chief Executive Officer at Opus Genetics, Inc..

“On October 30 , 2023, the Board of Directors (the “Board” ) of Ocuphire Pharma, Inc. (the “Company” ) appointed Dr. George Magrath, age 39, as the Company’s Chief Executive Officer, effective as of November 1, 2023.”

Opus Genetics, Inc. reported second quarter ended June 30, 2023 results: revenue approximately $40.0 million, net income Net loss for the three and six months e.

“Results for Second Quarter 2023 and Provides Corporate Update End-of-Phase 2 Meeting with FDA Scheduled for Q4 2023 for Oral APX3330 in Diabetic Retinopathy (DR) Cash Balance of $40 Million Expected to Fund Operations into 2025 Nyxol RM PDUFA date September 28, 2023; Approval would trigger $10 million milestone payment to Ocuphire Common Share Purchase Agreement”

Opus Genetics, Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $50,000,000 (effective 2023-08-10).

“On August 10, 2023, Ocuphire Pharma, Inc. (the “Company”) entered into a common stock purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), which provides that, upon the terms and subject to the conditions and limitations set forth therein, the Company has the right, but not the obligation, to sell to Lincoln Park up to $50,000,000 of shares of the Company’s common stock (the “Purchase Shares”) from time to time over the 30-month term of the Purchase Agreement.”

Sooch departed as Chief Executive Officer at Opus Genetics, Inc..

“Pursuant to the Separation and Release Agreement, Ms. Sooch will receive certain benefits in connection with Ms. Sooch being terminated without cause on April 19, 2023.”

Opus Genetics, Inc. shareholders approved Advisory Recommendation on the Frequency of an Advisory Vote on Named Executive Officer Compensation at the 2023-06-06 meeting.

“Proposal 3 - Advisory Recommendation on the Frequency of an Advisory Vote on Named Executive Officer Compensation One Year Two Years Three Years Votes Abstain 4,180,454 293,529 1,447,777 218,710”

Opus Genetics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-06 meeting.

“Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm Votes For Votes Against Votes Abstain 11,172,192 19,672 36,479”

Opus Genetics, Inc. shareholders approved Election of Directors at the 2023-06-06 meeting.

“Proposal 1 - Election of Directors Nominee Votes For Votes Withheld Broker Non-Votes Cam Gallagher 4,488,270 1,652,200 5,087,873 Sean Ainsworth 5,370,425 770,045 5,087,873 James Manuso 5,318,419 822,051 5,087,873 Richard Rodgers 4,538,415 1,602,054 5,087,873 Susan Benton 5,351,488 788,982 5,087,873 Jay Pepose 5,314,552 825,918 5,087,873”

Opus Genetics, Inc.: Reduced stockholder meeting quorum from a majority to one-third of voting power (effective 2023-06-01).

“The Bylaws Amendment amended Section 8 of ARTICLE III of the Bylaws to reduce the quorum requirement for all meetings of stockholders of the Company from a majority of the voting power of the outstanding shares of stock entitled to vote to one-third of the voting power of the outstanding shares of stock entitled to vote.”

Opus Genetics, Inc. reported first quarter ended March 31, 2023 results: revenue 1.7 million, net income -5.8 million, EPS -0.28.

“has no debt. Based on current projections, management believes the present cash on hand will be sufficient to fund operations into 2025. License and collaborations revenue was $1.7 million for the three months ended March 31, 2023. There was no revenue recorded in the three months ended March 31, 2022. Revenue during the first quarter of 2023 was derived from the”

Richard Rodgers was appointed as interim President and Chief Executive Officer at Opus Genetics, Inc..

“On April 19, 2023, the Board of Directors o f the Company (the “ Board ”) appointed Richard Rodgers as the Company’s interim President and Chief Executive Officer effective as of April 19 , 2023.”

Mina Sooch was terminated as President and Chief Executive Officer at Opus Genetics, Inc..

“On April 19, 2023, Ocuphire Pharma, Inc. (the “ Company ”) terminated the employment of Mina Sooch, the President and Chief Executive Officer of the Company.”

Opus Genetics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.

“Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.”

Opus Genetics, Inc. entered into License and Collaboration Agreement with FamyGen Life Sciences, Inc. valued at upfront cash payment of $35 million; potential additional payments of up to $130 million in the aggr (effective 2022-11-06).

“On November 6, 2022, Ocuphire Pharma, Inc. (“ Ocuphire ”) entered into a License and Collaboration Agreement (the “ License Agreement ”) with FamyGen Life Sciences, Inc. (“ Famy ”), pursuant to which Ocuphire granted Famy an exclusive, perpetual, sub-licensable license to develop, manufacture, import, export and commercialize (i) Nyxol for treating (a) reversal of mydriasis, (b) night vision disturbances or dim light vision, and (c) presbyopia, and (ii) Nyxol and low dose pilocarpine for treating presbyopia (together, the “ Products ”) worldwide except for certain countries and jurisdictions in Asia (the “ Territory ”).”

Opus Genetics, Inc. reported financial results for quarter ended September 30, 2022.

“On November 4, 2022, Ocuphire Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.”